Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above 200-Day Moving Average – Time to Sell?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)’s stock price crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $3.19 and traded as high as $5.38. Cumberland Pharmaceuticals shares last traded at $5.19, with a volume of 358,417 shares traded.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Cumberland Pharmaceuticals Price Performance

The business’s 50 day moving average price is $2.93 and its 200-day moving average price is $3.19. The company has a quick ratio of 1.11, a current ratio of 1.23 and a debt-to-equity ratio of 0.20. The company has a market cap of $77.63 million, a PE ratio of -21.63 and a beta of -0.53.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its quarterly earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter. Cumberland Pharmaceuticals had a negative net margin of 8.06% and a positive return on equity of 5.13%. The firm had revenue of $8.29 million for the quarter.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Bridgeway Capital Management LLC boosted its holdings in Cumberland Pharmaceuticals by 2.3% in the second quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock valued at $631,000 after purchasing an additional 4,200 shares during the last quarter. Two Sigma Investments LP raised its position in shares of Cumberland Pharmaceuticals by 16.5% in the 3rd quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after purchasing an additional 5,326 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Cumberland Pharmaceuticals during the 2nd quarter valued at approximately $34,000. Dimensional Fund Advisors LP grew its position in shares of Cumberland Pharmaceuticals by 11.1% during the third quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock worth $876,000 after buying an additional 27,980 shares in the last quarter. Finally, Heron Bay Capital Management acquired a new stake in shares of Cumberland Pharmaceuticals during the second quarter worth approximately $111,000. Institutional investors and hedge funds own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.